CrossrefInfokarte
Letter to the editor regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”
International Forum of Allergy & Rhinology · 2026-11 · 16 (11) · 1383-1384
DOI: 10.1002/alr.70291 ↗Abstract
Kein Abstract verfügbar.
EUVIMED